Richard D. DiMarchi

机构：Novo Nordisk (United States), Indiana University Bloomington, Institut des Maladies Métaboliques et Cardiovasculaires, Indiana University, University of Cincinnati Medical Center · ORCID：0000-0003-0220-4085

发表论文 300 篇 · 总被引 20612 次 · h-index 73

代表论文

• Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes (2022 · Frontiers in Endocrinology · 被引 152)
• GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications (2023 · Cell Metabolism · 被引 149)
• Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022 · Molecular Metabolism · 被引 147)
• Zn-regulated GTPase metalloprotein activator 1 modulates vertebrate zinc homeostasis (2022 · Cell · 被引 124)
• Transforming obesity: The advancement of multi-receptor drugs (2024 · Cell · 被引 120)
• Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice (2023 · Nature Metabolism · 被引 111)